{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:08:48Z","timestamp":1790723328606,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jacc.2021.09.004","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T17:34:11Z","timestamp":1635183251000},"page":"1831-1843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Familial Hypercholesterolemia"],"prefix":"10.1016","volume":"78","author":[{"given":"Julia","family":"Brandts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2021.09.004_bib1","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.09.004_bib2","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. a position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.09.004_bib3","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.09.004_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2015.04.809","article-title":"Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology","volume":"241","author":"De Backer","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2021.09.004_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2021.01.003","article-title":"LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: analysis from the secondary prevention 4S trial","volume":"320","author":"Vallejo-Vaz","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2021.09.004_bib6","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1161\/CIRCULATIONAHA.117.027966","article-title":"Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190\u00a0mg\/dl or above","volume":"136","author":"Vallejo-Vaz","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.09.004_bib7","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jacl.2016.04.009","article-title":"Familial hypercholesterolemia\/autosomal dominant hypercholesterolemia: molecular defects, the LDL-C continuum, and gradients of phenotypic severity","volume":"10","author":"Foody","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2021.09.004_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.09.004_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-014-0465-6","article-title":"Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances","volume":"17","author":"Stefanutti","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacc.2021.09.004_bib10","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1161\/CIRCULATIONAHA.119.043406","article-title":"Low density lipoprotein cholesterol\u2013lowering strategies and population health: time to move to a cumulative exposure model","volume":"141","author":"Brandts","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.09.004_bib11","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.09.004_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2021.03.042","article-title":"A\u00a0meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia","volume":"325","author":"Brandts","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2021.09.004_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.09.004_bib14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial","volume":"76","author":"Blom","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.09.004_bib15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","article-title":"Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study","volume":"5","author":"Raal","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2021.09.004_bib16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1517\/13543776.2015.1007954","article-title":"Fibronectin-based scaffold domain proteins that bind myostatin: a patent evaluation of WO2014043344","volume":"25","author":"Walker","year":"2015","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.jacc.2021.09.004_bib17","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.atherosclerosis.2019.06.019","article-title":"Safety, tolerability and LDL-C reduction with a novel anti-pcsk9 recombinant fusion protein (Lib003): results of a randomized, double-blind, placebo-controlled, phase 2 study","volume":"287","author":"Stein","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2021.09.004_bib18","first-page":"A17222","article-title":"Abstract 17222: safety, tolerability and LDL-C reduction with LIB003 a novel anti-PCSK9 recombinant fusion protein: results of open-label extension phase 2B study","volume":"140","author":"Stein","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.09.004_bib20","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.jacc.2021.09.004_bib21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jacc.2021.09.004_bib22","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.09.004_bib23","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.09.004_bib24","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.atherosclerosis.2019.06.018","article-title":"Inclisiran durably lowers LDL-C and Pcsk9 expression in subjects with homozygous familial hypercholesterolaemia: the Orion-2 pilot study","volume":"287","author":"Raal","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2021.09.004_bib25","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice","volume":"48","author":"Graham","year":"2007","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2021.09.004_bib26","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.ajkd.2013.02.359","article-title":"Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9","volume":"62","author":"van Poelgeest","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2021.09.004_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe9117","article-title":"An oral antisense oligonucleotide for PCSK9 inhibition","volume":"13","author":"Gennemark","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jacc.2021.09.004_bib28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/nat.2016.0623","article-title":"Disposition and pharmacokinetics of a GalNAc3-conjugated antisense oligonucleotide targeting human lipoprotein (a) in monkeys","volume":"26","author":"Yu","year":"2016","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jacc.2021.09.004_bib29","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.09.004_bib30","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom Randomized Clinical Trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.jacc.2021.09.004_bib31","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.atherosclerosis.2020.10.050","article-title":"Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials","volume":"315","author":"Duell","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2021.09.004_bib33","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.09.004_bib34","doi-asserted-by":"crossref","first-page":"158791","DOI":"10.1016\/j.bbalip.2020.158791","article-title":"Angiopoietin-like protein 3, an emerging cardiometabolic therapy target with systemic and cell-autonomous functions","volume":"1865","author":"Ruhanen","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.jacc.2021.09.004_bib35","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.09.004_bib36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.09.004_bib37","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.09.004_bib38","doi-asserted-by":"crossref","first-page":"A15751","DOI":"10.1161\/circ.142.suppl_3.15751","article-title":"Abstract 15751: pharmacodynamic effect of ARO-ANG3, an investigational RNA interference targeting hepatic angiopoietin-like protein 3, in patients with hypercholesterolemia","volume":"142","author":"Watts","year":"2020","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacc.2021.09.004_bib39","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.drudis.2021.03.016","article-title":"Pathophysiology and inhibition of cholesteryl ester transfer protein for prevention of cardiovascular diseases: an update","volume":"26","author":"Banerjee","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jacc.2021.09.004_bib40","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.09.004_bib41","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.09.004_bib42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11599310-000000000-00000","article-title":"On-and off-target pharmacology of torcetrapib","volume":"72","author":"Johns","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.jacc.2021.09.004_bib43","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.09.004_bib44","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(14)62115-2","article-title":"Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"385","author":"Kastelein","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.09.004_bib45","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.09.004_bib46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.119.042476","article-title":"In\u00a0Vivo AAV-CRISPR\/Cas9\u2013mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia","volume":"141","author":"Zhao","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.09.004_bib48","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In\u00a0vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2021.09.004_bib49","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cell.2014.02.001","article-title":"Crystal structure of Cas9 in complex with guide RNA and target DNA","volume":"156","author":"Nishimasu","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jacc.2021.09.004_bib50","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.117.031335","article-title":"Reduced blood lipid levels with in\u00a0vivo CRISPR-Cas9 base editing of ANGPTL3","volume":"137","author":"Chadwick","year":"2018","journal-title":"Circulation"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721061131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721061131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:45:43Z","timestamp":1760017543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721061131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":47,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0735109721061131"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.09.004","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Familial Hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}